Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Biohacking | Biohacking |
| Evidence strength | Early-stage evidence | Early-stage evidence |
| Evidence Score | 2/5 | 2/5 |
| User rating | 3.6 (29) | 4.3 (58) |
| Typical dose | In Russian clinical practice: usually 10–20 mg twice daily; dosing in informal, uncontrolled sources varies more widely, with no clearly established, human-study-confirmed safe upper limit | Exclusively within approved clinical trials: a single 25 mg dose (the "therapeutic" dose in the COMPASS Pathways trial) or a two-session protocol of 20–30 mg in the Johns Hopkins trial, each time under the direct supervision of two trained therapists in a clinical office. |
| Form | Tablets (Russian pharmaceutical preparation) or powder/capsules sold as a 'research chemical' outside Russia, without external quality control | Synthetic, standardized psilocybin in capsule form — not natural mushrooms with variable, unpredictable active-substance content. |
| Average price | Jako "research chemical": ok. 60–120 zł za opakowanie starczające na miesiąc, zależnie od źródła i braku standaryzacji | — |
| Monthly cost | ok. 60–120 zł/miesiąc, przy czym cena nie odzwierciedla kontrolowanej jakości produktu | — |
| Time to effects | Subjective effects are sometimes reported within days to a few weeks in informal user accounts, but no controlled study in healthy humans has confirmed a clear time course or the actual magnitude of any effect. | Subjective, acute psychedelic effects appear 20–40 minutes after dosing and last 4–6 hours. The antidepressant effect, if it occurs, tends to be noticeable within days of the session, and in the COMPASS Pathways trial was still partially measured at 12 weeks — though in some patients it faded over time and required consideration of another session or a return to standard treatment. |
| Who it's for | There's no well-established, solidly-evidenced target group in Western markets, where the substance isn't an approved drug | Exclusively participants in approved clinical trials on treatment-resistant depression, qualified after detailed psychiatric assessment |